21-hydroxylase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
The incidence of 21-hydroxylase deficient congenital adrenal hyperplasia detectable in childhood is approximately 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated [[newborn screening]] tests. The incidence of simple [[virilizing]] congenital adrenal hyperplasia is about 1 in 60,000 children. | The incidence of 21-hydroxylase deficient congenital adrenal hyperplasia detectable in childhood is approximately 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated [[newborn screening]] tests. The incidence of simple [[virilizing]] congenital adrenal hyperplasia is about 1 in 60,000 children.<ref name="Wikipeadia">https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency</ref> | ||
==Prevalence== | |||
The prevalence of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is approximately 1 per 100 individuals in certain population.<ref name="Wikipeadia">https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency</ref><ref name="pmid16912124">{{cite journal| author=New MI| title=Extensive clinical experience: nonclassical 21-hydroxylase deficiency. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 11 | pages= 4205-14 | pmid=16912124 | doi=10.1210/jc.2006-1645 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16912124 }} </ref> | |||
== References == | == References == | ||
Revision as of 18:47, 18 September 2015
|
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency epidemiology and demographics |
|
FDA on 21-hydroxylase deficiency epidemiology and demographics |
|
CDC on 21-hydroxylase deficiency epidemiology and demographics |
|
21-hydroxylase deficiency epidemiology and demographics in the news |
|
Blogs on 21-hydroxylase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
|
Risk calculators and risk factors for 21-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
The incidence of 21-hydroxlase deficient congenital adrenal hyperplasia is approximately 1 per 15,000 births.
Epidemiology and Demographics
Incidence
The incidence of 21-hydroxylase deficient congenital adrenal hyperplasia detectable in childhood is approximately 1 in 15,000 births. The severe salt-wasting form accounts for the majority of these cases, which is high enough that many states and countries routinely include it in mandated newborn screening tests. The incidence of simple virilizing congenital adrenal hyperplasia is about 1 in 60,000 children.[1]
Prevalence
The prevalence of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is approximately 1 per 100 individuals in certain population.[1][2]
References
- ↑ 1.0 1.1 https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency
- ↑ New MI (2006). "Extensive clinical experience: nonclassical 21-hydroxylase deficiency". J Clin Endocrinol Metab. 91 (11): 4205–14. doi:10.1210/jc.2006-1645. PMID 16912124.